All lobbying filings

TULIPIFERA STRATEGIES

TULIPIFERA STRATEGIES filed a Q2 termination report for TREATMENT ADVOCACY CENTER on August 28, 2026, reporting $10,000 in lobbying income.

Lobbying for TREATMENT ADVOCACY CENTER · Advocacy, education, and research related to eliminating barriers to the treatment of SMI.

All filings by TULIPIFERA STRATEGIES · Everything TREATMENT ADVOCACY CENTER has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Aug 28, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Virginia

Representation ended

Jun 30, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Medicaid IMD Exclusion. The IMD Exclusion, within Sec. 1905(a) of the Social Security Act, generally excludes federal fund participation for treatment provided in an inpatient psychiatric facility. Medicare lifetime limit on impatient psychiatric care. Medicare generally imposes a 190 day lifetime limit on treatment provided in an inpatient psychiatric facility.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.